PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2017 RESULTS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Russia says it could strike UK military targets in response to Kyiv's use of British missiles
Pfizer (PFE) PT Raised to $42 at Deutsche Bank Following 4Q
January 31, 2018 7:39 AM ESTDeutsche Bank raised its price target on Pfizer (NYSE: PFE) to $42.00 (from $41.00) while maintaining a Buy rating following 4Q. PFE reported 4Q EPS of $0.62, well above consensus of $0.56. Revenue came in just above estimates, while gross margin was lower and operating expenses were... More
Pfizer (PFE) Tops Q4 EPS by 6c, FY18 EPS Guidance Beats, Sees $15B Repatriation Tax Liability
January 30, 2018 6:46 AM EST(Updated - January 30, 2018 6:49 AM EST)
Pfizer (NYSE: PFE) reported Q4 EPS of $0.62, $0.06 better than the analyst estimate of $0.56. Revenue for the quarter came in at $13.7 billion versus the consensus estimate of $13.68 billion.
Pfizers 2018 financial guidance is presented below. Financial guidance reflects... More
